Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Acetylsalicylic Acid Reduces Niacin Extended-Release-Induced Flushing in Patients with Dyslipidemia

Acetylsalicylic Acid Reduces Niacin Extended-Release-Induced Flushing in Patients with Dyslipidemia Am J Cardiovasc Drugs 2009; 9 (2): 69-79 ORIGINAL RESEARCH ARTICLE 1175-3277/09/0002-0069/$49.95/0 ª 2009 Adis Data Information BV. All rights reserved. Acetylsalicylic Acid Reduces Niacin Extended-Release-Induced Flushing in Patients with Dyslipidemia 1 2,3 4 1 1 1 Roopal B. Thakkar, Moti L. Kashyap, Andrew J. Lewin, Scott L. Krause, Ping Jiang and Robert J. Padley 1 Abbott Laboratories, Abbott Park, Illinois, USA 2 Atherosclerosis Research Center, Department of Veterans Affairs Medical Center, Long Beach, California, USA 3 Department of Medicine, University of California, Irvine, California, USA 4 National Research Institute, Los Angeles, California, USA Abstract Background: Niacin extended-release (NER) is safe and effective for treatment of dyslipidemia. However, some patients discontinue NER treatment because of flushing, the most common adverse event associated with niacin therapy. Objective: To evaluate the effect of daily oral acetylsalicylic acid (ASA) on NER-induced flushing in patients with dyslipidemia. Methods: A randomized, double-blind, placebo-controlled, multicenter, 5-week study was conducted (Clinical- Trials.gov identifier: NCT00626392). Patients (n= 277) were randomly assigned to one of six treatment arms and received a 1-week run-in with ASA 325 mg or placebo followed by 4 weeks of ASA 325 mg or placebo 30 minutes before NER at a starting dose of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Acetylsalicylic Acid Reduces Niacin Extended-Release-Induced Flushing in Patients with Dyslipidemia

Loading next page...
 
/lp/springer-journals/acetylsalicylic-acid-reduces-niacin-extended-release-induced-flushing-IA00a5wK1M

References (3)

Publisher
Springer Journals
Copyright
Copyright © 2009 by Adis Data Information BV
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.1007/BF03256578
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs 2009; 9 (2): 69-79 ORIGINAL RESEARCH ARTICLE 1175-3277/09/0002-0069/$49.95/0 ª 2009 Adis Data Information BV. All rights reserved. Acetylsalicylic Acid Reduces Niacin Extended-Release-Induced Flushing in Patients with Dyslipidemia 1 2,3 4 1 1 1 Roopal B. Thakkar, Moti L. Kashyap, Andrew J. Lewin, Scott L. Krause, Ping Jiang and Robert J. Padley 1 Abbott Laboratories, Abbott Park, Illinois, USA 2 Atherosclerosis Research Center, Department of Veterans Affairs Medical Center, Long Beach, California, USA 3 Department of Medicine, University of California, Irvine, California, USA 4 National Research Institute, Los Angeles, California, USA Abstract Background: Niacin extended-release (NER) is safe and effective for treatment of dyslipidemia. However, some patients discontinue NER treatment because of flushing, the most common adverse event associated with niacin therapy. Objective: To evaluate the effect of daily oral acetylsalicylic acid (ASA) on NER-induced flushing in patients with dyslipidemia. Methods: A randomized, double-blind, placebo-controlled, multicenter, 5-week study was conducted (Clinical- Trials.gov identifier: NCT00626392). Patients (n= 277) were randomly assigned to one of six treatment arms and received a 1-week run-in with ASA 325 mg or placebo followed by 4 weeks of ASA 325 mg or placebo 30 minutes before NER at a starting dose of

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Aug 17, 2012

There are no references for this article.